Andexxa Injection, Powder, Lyophilized, For Solution
Product Images NDC 0310-3200

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Andexxa (NDC 0310-3200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Andexxa 01)

An instructional illustration showing a gloved hand holding a vial, while a syringe needle is inserted into the vial's rubber stopper, depicting preparation for drawing up an injection dose.*

FDA Label Image

Figure A (Andexxa 02)

An instructional illustration showing hands wearing gloves holding a vial with arrows indicating a twisting or opening motion, likely demonstrating how to open or prepare the vial for use.*

FDA Label Image

Figure B (Andexxa 03)

Illustration showing a hand holding a vial of ANDEXXA (andexanet alfa) injection, powder, lyophilized, for solution. The image depicts the technique for rotating the vial, likely to mix or reconstitute the lyophilized powder before intravenous administration.*

FDA Label Image

Figure Ii (Andexxa 04)

An instructional illustration depicting how to open a package or pouch using both hands. One hand pulls back the package flap while the other holds the package steady.*

FDA Label Image

Figure A 14 (Andexxa 05)

A line graph comparing anti-Xa levels (ng/mL) over 24 hours following bolus and infusion treatments. The graph shows two data series: one for placebo bolus plus 2-hour infusion and another for ANDEXXA 400 mg bolus plus 480 mg 2-hour infusion. Time after bolus (hours) is on the x-axis, and anti-Xa level is on the y-axis, with markers indicating end of bolus and end of infusion.*

FDA Label Image

Figure B 14 (Andexxa 06)

A line graph comparing Anti-Xa levels (ng/mL) over time (hours) after bolus administration between placebo and ANDEXXA (andexanet alfa) treatment groups. The graph shows data points from 0 to 24 hours, with annotations marking the end of bolus and infusion periods, illustrating the pharmacodynamic response following intravenous administration.*

FDA Label Image

Carton 200mg mL (Andexxa 07)

The label for ANDEXXA 200 mg/vial is an intravenous injection lyophilized powder of coagulation factor Xa (recombinant), inactivated-zhzo. The packaging indicates single-dose vials with no preservative, and provides storage instructions and reconstitution details. Manufactured by AstraZeneca AB and distributed by AstraZeneca Pharmaceuticals LP, the label includes the product NDC 0310-3200-04 and states it is Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.